Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates inhibition of Japanese cedar pollen allergic rhinitis via TLR4 agonist glucopyranosyl lipid A, suggesting new avenues for allergy immunotherapy.
To the Editor, The most common cause of seasonal allergic rhinitis (AR) in Japan is Japanese cedar (JC) pollen. Airway allergic inflammation has been re‐ ported to be suppressed by toll‐like receptor 4 (TLR4) agonists such as MPLA.1 Glucopyranosyl lipid A (GLA), a synthetic TLR4 agonist, is a novel synthetic nontoxic analog of lipid A with strong activity to promote Th1 immune responses.2 The safety and immunogenicity of GLA has been shown in phase 2 clinical trial.3 We evaluated the effect of GLA on JC pollen‐induced cytokine responses in human peripheral blood mononuclear cells (PBMC) and clinical symptoms in a murine JC challenge model. PBMC isolated from Japanese cedar pollinosis (JCP) patients were incubated with JC pollen extract (1‐100 μg/mL) for 6 days, with or without GLA in aqueous formulation (GLA‐AF) at different concentrations (0.03‐3 μg/mL), and secretion of IL‐5, IL‐13, IFN‐γ, and IL‐10 was measured by ELISA (Figure 1A‐H). JC pollen extract maximally stimulated IL‐5 secretion at 10 μg/mL (Figure 1A), which was significantly inhibited by GLA‐AF (0.3 and 3 μg/mL) (Figure 1B). The secretion of IL‐13 was not significantly different in presence and absence of GLA (Figure 1C). 10 μg/ml of Cry j 1, which is the major allergen of JC pollen, also induced IL‐5 secretion from PBMC and the secretion of IL‐5 was significantly suppressed by GLA (3 μg/ml)
No takes yet. Share an insight, caveat, or question.
Matsumoto et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: